Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the in vitro ADME testing services market and its likely evolution in the short-mid and long term.

Chapter 3 provides an introduction to the overall drug discovery process, with details on the time taken for a drug to traverse through the various stages of drug development and into the market. It includes an overview of ADME testing, featuring a detailed discussion on the significance of evaluating various ADME parameters within the drug discovery and development process. Further, the chapter presents insights on the benefits of carrying out ADME testing at early stages of drug development. It also features details related to various contract services that can be availed by industry stakeholders seeking to outsource ADME testing.

Chapter 4 features a detailed discussion on the various outsourcing related business models that are commonly adopted by the industry stakeholders in relation to ADME testing. The chapter includes a list of factors that drive sponsors to outsource their ADME testing operations. It also highlights several key parameters that sponsors need to take into consideration while choosing a CRO partner. The chapter features an elaborate discussion on benefits of outsourcing ADME services, along with the affiliated risks and challenges.

Chapter 5 provides a comprehensive view on the global landscape of in vitro ADME testing service providers. It includes information related to over 90 CROs that claim to offer in vitro ADME services, featuring in-depth analyses of the players based on their year of establishment, headquarter location(s), company size, type of additional service(s) offered, range of assays offered within in vitro ADME service portfolio, type of molecule(s), and type of clientele. The chapter also includes a list of 70 players offering in silico ADME services. In addition, it also features a logo landscape of the players that claim to offer in vitro ADME services, distributed on the basis of the location of their respective headquarters and company size.

Chapter 6 features detailed profiles of key CROs that claim to offer in vitro ADME testing services, across different geographies. Each company profile includes a brief overview of the company, financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to in vitro ADME testing. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 8 features a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2005 to 2018. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.

Chapter 9 features information on the regulatory guidelines that have been laid down by key regulatory bodies / organizations, specific to ADME testing in the pharmaceutical industry. These are EMA, ICH, MHLW, OECD, USFDA and WHO.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of in vitro ADME testing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the biopharmaceutical industry.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Dan Close (Chief Scientific Officer, 490 BioTech), and Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. Chapter Overview
3.2. The Drug Discovery and Development Process
3.3. Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing
3.3.1. Absorption
3.3.2. Distribution
3.3.3. Metabolism
3.3.4. Excretion
3.4. Importance of ADME Studies in Early Stage Research
3.5. Types of ADME Studies in Discovery and Preclinical Development
3.6. Types of Assays Used in ADME Testing
3.7. Types of ADME Testing Studies
3.7.1. In Vitro ADME Testing Studies
3.7.2. In Silico ADME Testing Studies
3.7.3. In Vivo ADME Testing Studies
3.8. Key Drivers for ADME Testing Studies
3.9. Concluding Remarks

4 GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing ADME Testing Services
4.3. Guiding Models for Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance-based Outsourcing Model
4.3.3. Outcomes-based Outsourcing Model
4.3.4. Phase-dependent Outsourcing Model
4.4. Selecting a Contract Research Organization (CRO) Partner
4.4.1. Key Considerations
4.5. Role of CROs in Drug Development
4.5.1. Discovery and Preclinical Research
4.5.2. Early Clinical Research
4.5.3. Late Stage Clinical Research
4.6. Benefits of Outsourcing ADME Testing Services
4.7. Risks and Challenges Associated with Outsourcing ADME Testing Services
4.8. Concluding Remarks

5 MARKET LANDSCAPE
5.1. Chapter Overview
5.2. In Vitro ADME Testing Services: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Service Offering
5.2.5. Analysis by Type of In Vitro ADME Assays
5.2.6. Analysis by Type of Molecule
5.2.7. Analysis by Type of Clientele
5.2.8. Logo Landscape: Distribution by Company Size and Location of Headquarters
5.3. In Silico ADME Testing Services: List of Industry Players

6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Albany Molecular Research (AMRI)
6.2.1.1. Company Snapshot
6.2.1.2. Financial Information
6.2.1.3. ADME Testing Specific Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Charles River Laboratories
6.2.2.1. Company Snapshot
6.2.2.2. Financial Information
6.2.2.3. ADME Testing Specific Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Pharmaceutical Product Development (PPD)
6.2.3.1. Company Snapshot
6.2.3.2. ADME Testing Specific Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. RTI International
6.2.4.1. Company Snapshot
6.2.4.2. Financial Information
6.2.4.3. ADME Testing Specific Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. Eurofins Scientific
6.3.1.1. Company Snapshot
6.3.1.2. Financial Information
6.3.1.3. ADME Testing Specific Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Evotec
6.3.2.1. Company Snapshot
6.3.2.2. Financial Information
6.3.2.3. ADME Testing Specific Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Galapagos
6.3.3.1. Company Snapshot
6.3.3.2. Financial Information
6.3.3.3. ADME Testing Specific Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Tecan Group
6.3.4.1. Company Snapshot
6.3.4.2. Financial Information
6.3.4.3. ADME Testing Specific Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. GVK Biosciences
6.4.1.1. Company Snapshot
6.4.1.2. ADME Testing Specific Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Pharmaron
6.4.2.1. Company Snapshot
6.4.2.2. ADME Testing Specific Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. Sai Life Sciences
6.4.3.1. Company Snapshot
6.4.3.2. ADME Testing Specific Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Shanghai Medicilon
6.4.4.1. Company Snapshot
6.4.4.2. ADME Testing Specific Service Portfolio
6.4.4.3. Recent Developments and Future Outlook
6.4.5. Syngene International
6.4.5.1. Company Snapshot
6.4.5.2. Financial Information
6.4.5.3. ADME Testing Specific Service Portfolio
6.4.5.4. Recent Developments and Future Outlook
6.4.6. WuXi AppTec
6.4.6.1. Company Snapshot
6.4.6.2. Financial Information
6.4.6.3. ADME Testing Specific Service Portfolio
6.4.6.4. Recent Developments and Future Outlook

7 BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
7.4. Concluding Remarks

8 MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. In Vitro ADME Testing Services: Mergers and Acquisitions
8.2.1. Cumulative Year-wise Trend
8.2.2. Geographical Activity
8.2.3. Ownership Change Matrix
8.2.4. Most Active Players: Analysis by Number of Acquisitions
8.2.5. Key Value Drivers
8.2.6. Key Acquisitions: Deal Multiples

9 REGULATORY RECOMMENDATIONS AND GUIDELINES
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Regulatory Agencies
9.2.1. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
9.2.2. World Health Organization (WHO)
9.2.3. Organisation for Economic Co-operation and Development (OECD)
9.3. Regulatory Guidelines Issued by Regional Regulatory Agencies
9.3.1. United States Food and Drug Administration (USFDA), US
9.3.2. European Medicine Agency (EMA), Europe
9.3.3. Ministry of Health, Labour and Welfare (MHLW), Japan
9.4. In Vitro ADME Testing Service Providers: Information on Regulatory Approval

10 MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall In Vitro ADME Testing Services Market, 2019-2030
10.4. In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030
10.4.1. In Vitro ADME Testing Services Market in North America, 2019-2030
10.4.1.1. In Vitro ADME Testing Services Market in the US, 2019-2030
10.4.1.2. In Vitro ADME Testing Services Market in Canada, 2019-2030
10.4.2. In Vitro ADME Testing Services Market in Europe, 2019-2030
10.4.2.1. In Vitro ADME Testing Services Market in Germany, 2019-2030
10.4.2.2. In Vitro ADME Testing Services Market in France, 2019-2030
10.4.2.3. In Vitro ADME Testing Services Market in the UK, 2019-2030
10.4.2.4. In Vitro ADME Testing Services Market in Italy, 2019-2030
10.4.2.5. In Vitro ADME Testing Services Market in Spain, 2019-2030
10.4.2.6. In Vitro ADME Testing Services Market in Rest of Europe, 2019-2030
10.4.3. In Vitro ADME Testing Services Market in Asia-Pacific and Rest of the World, 2019-2030
10.4.3.1. In Vitro ADME Testing Services Market in Japan, 2019-2030
10.4.3.2. In Vitro ADME Testing Services Market in China, 2018-2028
10.4.3.3. In Vitro ADME Testing Services Market in India, 2019-2030
10.4.3.4. In Vitro ADME Testing Services Market in Rest of the World, 2019-2030
10.5. In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030
10.5.1. In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030
10.5.2. In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030
10.5.3. In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030
10.5.4. In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030
10.6. In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030
10.6.1. In Vitro ADME Testing Services Market for Caco-2 Permeability Assay, 2019-2030
10.6.2. In Vitro ADME Testing Services Market for Protein Binding Assay, 2019-2030
10.6.3. In Vitro ADME Testing Services Market for Metabolic Stability / Clearance Assay, 2019-2030
10.6.4. In Vitro ADME Testing Services Market for Enzyme Induction Assay, 2019-2030
10.6.5. In Vitro ADME Testing Services Market for Enzyme Inhibition Assay, 2019-2030
10.6.6. In Vitro ADME Testing Services Market for Other Assays, 2019-2030
10.7. In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030
10.7.1. In Vitro ADME Testing Services Market for Small Molecules, 2019-2030
10.7.2. In Vitro ADME Testing Services Market for Biologics, 2019-2030
10.8. In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030
10.8.1. In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030
10.8.2. In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030
10.8.3. In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030
10.8.4. In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030
10.8.5. In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030
10.8.6. In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030
10.8.7. In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030
10.8.8. In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030
10.8.9. In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030
10.8.10. In Vitro ADME Testing Services Market for Cancers, 2019-2030
10.8.11. In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030
10.8.12. In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030
10.8.13. In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030
10.8.14. In Vitro ADME Testing Services Market for Other Disorders, 2019-2030
10.8.15. In Vitro ADME Testing Services Market: Market Attractiveness Analysis by Therapeutic Areas, 2019-2030
10.9. In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030
10.9.1. In Vitro ADME Testing Services Market for Industry Players, 2019-2030
10.9.2. In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030

11 CONCLUSION
11.1. In Vitro ADME Studies Conducted During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Success in Clinical Trials
11.2. Several CROs Offer Services for In Vitro ADME Testing; Most such Companies are based in North America and Europe
11.3. The Market is Dominated by Players having Vast In Vitro ADME Testing Portfolios; Drug Metabolism-related Assays Represent a Major Fraction of Services
11.4. Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in Number of Acquisitions Reported over the Past Decade
11.5. Owing to the Benefits of Outsourcing, the In Vitro ADME testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

12 EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. 490 BioTech
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Dan Close, Chief Scientific Officer
12.3. JRF Global
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

13 APPENDIX 1: TABULATED DATA

14 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Pharmacokinetics Pathway of a Drug in Human Body
Figure 3.3 Comparison of Oral and Intravascular Drug Administration: Role of Hepatic Portal System
Figure 3.4 Reasons for Attrition in Drug Development
Figure 3.5 ADME Studies in Discovery and Preclinical Development
Figure 3.6 Drivers for In Vitro ADME Testing Studies
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance-based Outsourcing Model
Figure 4.4 Key Steps Leading to Outcomes-based Outsourcing Model
Figure 4.5 Factors Influencing Outsourcing Decisions
Figure 4.6 Key Considerations to Select a CRO Partner
Figure 4.7 Role of a CRO in Different Phases of Drug Development
Figure 4.8 End-to-End Integrated Services in Discovery and Preclinical Research
Figure 4.9 Benefits of Outsourcing ADME Testing Services
Figure 4.1 Challenges Related to Outsourcing ADME Testing Services
Figure 5.1 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Figure 5.2 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Figure 5.3 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Figure 5.4 In Vitro ADME Testing Service Providers: Distribution by Company Size
Figure 5.5 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Figure 5.6 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Figure 5.7 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Figure 5.8 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Figure 5.9 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Figure 5.1 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Figure 5.11 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Figure 5.12 In Vitro ADME Testing Service Providers Logo Landscape: Distribution by Company Size and Location
Figure 6.1 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.2 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.3 AMRI: In Vitro ADME Testing Service Portfolio
Figure 6.4 Charles River Laboratories: Business Segments
Figure 6.5 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Figure 6.6 Charles River Laboratories: In Vitro ADME Testing Service Portfolio
Figure 6.7 BioDuro: In Vitro ADME Assays Offered
Figure 6.8 RTI International: Annual Revenues, 2013-2017 (USD Million)
Figure 6.9 RTI International: In Vitro ADME Testing Service Portfolio
Figure 6.1 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Figure 6.11 Eurofins Scientific: In Vitro ADME Testing Service Portfolio
Figure 6.12 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Figure 6.13 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Figure 6.14 Evotec: Drug Discovery Services
Figure 6.15 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Figure 6.16 Galapagos: In Vitro ADME Testing Service Portfolio
Figure 6.17 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Figure 6.18 Tecan Group: In Vitro ADME Testing Service Portfolio
Figure 6.19 GVK Biosciences: Business Segments
Figure 6.2 GVK Biosciences: In Vitro ADME Testing Service Portfolio
Figure 6.21 Pharmaron: In Vitro ADME Service Portfolio
Figure 6.22 Sai Life Sciences: In Vitro ADME Testing Service Portfolio
Figure 6.23 Shanghai Medicilon: In Vitro ADME Testing Service Portfolio
Figure 6.24 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Figure 6.25 Syngene International: In Vitro ADME Testing Service Portfolio
Figure 6.26 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Figure 6.27 WuXi AppTec: In Vitro ADME Testing Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 7.1 Benchmark Analysis: Comparison Across Peer Groups
Figure 8.1 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Figure 8.2 Acquisitions: Regional Distribution
Figure 8.3 Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 8.4 Acquisitions: Ownership Change Matrix
Figure 8.5 Acquisitions: Most Active Acquirers
Figure 8.6 Acquisitions: Key Value Drivers
Figure 8.7 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Figure 9.1 Regulatory Guidelines for Non-Clinical Studies
Figure 9.2 ICH: Regulatory and Industry Participants
Figure 9.3 ICH: Guidance Documents for Non-Clinical Studies
Figure 9.4 USFDA: GLP Guidelines for Non-Clinical Studies
Figure 9.5 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Figure 10.1 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Figure 10.2 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.3 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Figure 10.4 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Billion)
Figure 10.5 In Vitro ADME Testing Services Market, 2019-2030: US, Base Scenario (USD Million)
Figure 10.6 In Vitro ADME Testing Services Market, 2019-2030: Canada, Base Scenario (USD Million)
Figure 10.7 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Billion)
Figure 10.8 In Vitro ADME Testing Services Market, 2019-2030: Germany, Base Scenario (USD Million)
Figure 10.9 In Vitro ADME Testing Services Market, 2019-2030: France, Base Scenario (USD Million)
Figure 10.1 In Vitro ADME Testing Services Market, 2019-2030: UK, Base Scenario (USD Million)
Figure 10.11 In Vitro ADME Testing Services Market, 2019-2030: Italy, Base Scenario (USD Million)
Figure 10.12 In Vitro ADME Testing Services Market, 2019-2030: Spain, Base Scenario (USD Million)
Figure 10.13 In Vitro ADME Testing Services Market, 2019-2030: Rest of Europe, Base Scenario (USD Million)
Figure 10.14 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Billion)
Figure 10.15 In Vitro ADME Testing Services Market, 2019-2030: Japan, Base Scenario (USD Million)
Figure 10.16 In Vitro ADME Testing Services Market, 2019-2030: China, Base Scenario (USD Million)
Figure 10.17 In Vitro ADME Testing Services Market, 2019-2030: India, Base Scenario (USD Million)
Figure 10.18 In Vitro ADME Testing Services Market, 2019-2030: Rest of the World, Base Scenario (USD Million)
Figure 10.19 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Figure 10.2 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Figure 10.21 In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.22 In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.23 In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.24 In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.25 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Figure 10.26 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Figure 10.27 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Caco-2 Permeability Assay, Base Scenario (USD Million)
Figure 10.28 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Protein Binding Assay, Base Scenario (USD Million)
Figure 10.29 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Metabolic Stability / Clearance Assay, Base Scenario (USD Million)
Figure 10.3 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Induction Assay, Base Scenario (USD Million)
Figure 10.31 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Inhibition Assay, Base Scenario (USD Million)
Figure 10.32 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Other Assays, Base Scenario (USD Million)
Figure 10.33 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Figure 10.34 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Figure 10.35 In Vitro ADME Testing Services Market for Small Molecules, 2019-2030: Base Scenario (USD Billion)
Figure 10.36 In Vitro ADME Testing Services Market for Biologics, 2019-2030: Base Scenario (USD Billion)
Figure 10.37 In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.38 In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.39 In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.4 In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.41 In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030: Base Scenario (USD Million)
Figure 10.42 In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.43 In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.44 In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.45 In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.46 In Vitro ADME Testing Services Market for Cancers, 2019-2030: Base Scenario (USD Million)
Figure 10.47 In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.48 In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.49 In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.5 In Vitro ADME Testing Services Market for Other Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.51 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
Figure 10.52 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Figure 10.53 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030
Figure 10.54 In Vitro ADME Testing Services Market for Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 10.55 In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 11.1 Overall In Vitro ADME Testing Services Market, Conservative, Base and Optimistic Scenarios, 2019, 2024 and 2030 (USD Billion)

List of Tables

Table 3.1 List of Assays Performed During ADME Studies
Table 5.1 In Vitro ADME Testing Services: List of Industry Players
Table 5.2 In Vitro ADME Testing Service Providers: Information on Type of In Vitro ADME Testing Services
Table 5.3 In Vitro ADME Testing Service Providers: Information on Type of Molecule
Table 5.4 In Vitro ADME Testing Service Providers: Information on Type of Clientele
Table 5.5 In Silico ADME Testing Services: List of Industry Players
Table 6.1 In Vitro ADME Testing Services: List of Companies Profiled
Table 6.2 AMRI: Key Highlights
Table 6.3 AMRI: Recent / Past Trends and Future Outlook
Table 6.4 Charles River Laboratories: Key Highlights
Table 6.5 Charles River Laboratories: Recent / Past Trends and Future Outlook
Table 6.6 BioDuro: Key Highlights
Table 6.7 BioDuro: Recent / Past Trends and Future Outlook
Table 6.8 RTI International: Key Highlights
Table 6.9 RTI International: Recent / Past Trends and Future Outlook
Table 6.10 Eurofins Scientific: Key Highlights
Table 6.11 Eurofins Scientific: Recent / Past Trends and Future Outlook
Table 6.12 Evotec: Key Highlights
Table 6.13 Evotec: In Vitro ADME Assays Offered
Table 6.14 Evotec: Recent / Past Trends and Future Outlook
Table 6.15 Galapagos: Key Highlights
Table 6.16 Galapagos: Recent / Past Trends and Future Outlook
Table 6.17 Tecan Group: Key Highlights
Table 6.18 Tecan Group: Recent / Past Trends and Future Outlook
Table 6.19 GVK Biosciences: Key Highlights
Table 6.20 GVK Biosciences: Recent / Past Trends and Future Outlook
Table 6.21 Pharmaron: Key Highlights
Table 6.22 Pharmaron: Recent / Past Trends and Future Outlook
Table 6.23 Sai Life Sciences: Key Highlights
Table 6.24 Sai Life Sciences: Recent / Past Trends and Future Outlook
Table 6.25 Shanghai Medicilon: Key Highlights
Table 6.26 Shanghai Medicilon: Recent / Past Trends and Future Outlook
Table 6.27 Syngene International: Key Highlights
Table 6.28 Syngene International: Recent / Past Trends and Future Outlook
Table 6.29 WuXi AppTec: Key Highlights
Table 6.30 WuXi AppTec: Recent / Past Trends and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 In Vitro ADME Testing Services: Mergers and Acquisitions
Table 8.2 In Vitro ADME Testing Services: Information on Key Value Drivers of Acquisitions
Table 8.3 Key Acquisitions: Deal Multiples
Table 9.1 USFDA: Guidance Documents for Non-Clinical Studies
Table 9.2 EMA: Guidance Documents for Non-Clinical Studies
Table 9.3 MHLW: Guidance Documents for Non-Clinical Studies
Table 9.4 In Vitro ADME Testing Service Providers: Information on Regulatory Approval
Table 12.1 490 BioTech: Key Highlights
Table 12.2 JRF Global: Key Highlights
Table 13.1 Reasons for Attrition in Drug Development
Table 13.2 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Table 13.3 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Table 13.4 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Table 13.5 In Vitro ADME Testing Service Providers: Distribution by Company Size
Table 13.6 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Table 13.7 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Table 13.8 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Table 13.9 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Table 13.10 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Table 13.11 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Table 13.12 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Table 13.13 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 13.14 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 13.15 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Table 13.16 RTI International: Annual Revenues, 2013-2017 (USD Million)
Table 13.17 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Table 13.18 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Table 13.19 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Table 13.20 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Table 13.21 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Table 13.22 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Table 13.23 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Table 13.24 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Table 13.25 Benchmark Analysis: Peer Group I
Table 13.26 Benchmark Analysis: Peer Group II
Table 13.27 Benchmark Analysis: Peer Group III
Table 13.28 Benchmark Analysis: Peer Group IV
Table 13.29 Benchmark Analysis: Peer Group V
Table 13.30 Benchmark Analysis: Peer Group VI
Table 13.31 Benchmark Analysis: Peer Group VII
Table 13.32 Benchmark Analysis: Peer Group VIII
Table 13.33 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Table 13.34 Acquisitions: Regional Distribution
Table 13.35 Acquisitions: Intercontinental and Intracontinental Acquisitions
Table 13.36 Acquisitions: Ownership Change Matrix
Table 13.37 Acquisitions: Most Active Acquirers
Table 13.38 Acquisitions: Key Value Drivers
Table 13.39 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Table 13.40 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Table 13.41 Overall In Vitro ADME Testing Services Market, 2019-2030: Conservative Scenario (USD Billion)
Table 13.42 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Table 13.43 Overall In Vitro ADME Testing Services Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 13.44 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Conservative Scenario (USD Billion)
Table 13.45 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Table 13.46 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 13.47 In Vitro ADME Testing Services Market, 2019-2030: North America, Conservative Scenario (USD Million)
Table 13.48 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Million)
Table 13.49 In Vitro ADME Testing Services Market, 2019-2030: North America, Optimistic Scenario (USD Million)
Table 13.50 In Vitro ADME Testing Services Market, 2019-2030: Europe, Conservative Scenario (USD Million)
Table 13.51 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Million)
Table 13.52 In Vitro ADME Testing Services Market, 2019-2030: Europe, Optimistic Scenario (USD Million)
Table 13.53 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
Table 13.54 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
Table 13.55 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
Table 13.56 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Table 13.57 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Conservative Scenario (USD Million)
Table 13.58 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Table 13.59 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Optimistic Scenario (USD Million)
Table 13.60 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Table 13.61 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Conservative Scenario (USD Million)
Table 13.62 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Table 13.63 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Optimistic Scenario (USD Million)
Table 13.64 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Table 13.65 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Conservative Scenario (USD Billion)
Table 13.66 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Table 13.67 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Optimistic Scenario (USD Billion)
Table 13.68 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Table 13.69 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
Table 13.70 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
Table 13.71 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
Table 13.72 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
Table 13.73 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Billion)
Table 13.74 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Table 13.75 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Billion)
Table 13.76 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 490 BioTech
2. Aaranya Biosciences
3. AbbVie
4. Accelera
5. Advanced Chemistry Development Labs
6. Admescope
7. ADMETRx
8. Advancell Advanced In Vitro Cell Technologies
9. Agilux Laboratories
10. Allesh Biosciences Labs
11. Altasciences
12. AMRI
13. Analiza
14. Antengene
15. APEIRON Biologics
16. APhaD
17. Apredica
18. Aptuit
19. Aragen Bioscience
20. Aravali Pharma & Lifesciences
21. Asahi Kasei Pharma
22. Astellas Analytical Science Laboratories
23. AstraZeneca
24. Aurigon
25. Aurora Fine Chemicals
26. Avistron Chemistry Services
27. Baxter
28. Biaffin
29. Bienta
30. BioAscent
31. Biocon
32. BioDuro
33. BioIVT
34. Bionomics
35. Biotech Investment Group
36. Biotranex
37. BLIRT
38. BloodCenter of Wisconsin
39. Blue Stream Laboratories
40. BOC Sciences
41. Brains On-Line
42. BRI Biopharmaceutical Research
43. Brunswick Labs
44. Caliper Life Sciences
45. Calvert Laboratories
46. CanAm Bioresearch
47. Cangenix
48. CapEval Pharma
49. Carna Biosciences
50. Carrick Therapeutics
51. CeeTox
52. Celgene
53. Cellumen
54. Celsis In Vitro Technologies
55. Celsis International
56. CEMSA - Center for Applied Mass Spectrometry
57. Charles River Laboratories
58. ChemBio Discovery Solutions
59. ChemDiv
60. ChemModeling
61. ChemoGenics BioPharma
62. Chemotargets
63. ChemPartner
64. Citoxlab Group
65. Clinical Research Laboratories
66. Cloud Pharmaceuticals
67. Colorado Computational
68. Comparative Biosciences
69. CompChem Solutions
70. Concept Life Sciences
71. Concord Biosciences
72. Corning Life Sciences
73. Covance
74. CR Medicon
75. Creative Animodel
76. Creative Biolabs
77. Creative Biostructure
78. Crelux
79. Crucell
80. Cyclica
81. Cyprotex
82. Dermscan
83. DiaSorin
84. Discover Drugs
85. Distributed Bio
86. Domainex
87. Drik
88. eADMET
89. Eagle Pharmaceuticals
90. ECOSUR
91. EMD Millipore
92. Enamine 
93. Entelos
94. Envigo
95. EnvironeX Group
96. Eurofins Scientific
97. Eurofins Cerep
98. European Federation of Pharmaceutical Industries and Associations
99. Eurosafe
100. Evolvus
101. Evotec
102. Excelra Knowledge Solutions
103. Exscientia
104. Fidelta
105. Formex
106. Frontage Laboratories 
107. Gadea Pharmaceutical Group
108. Galapagos
109. Genentech
110. GenPharm Tox Biotech
111. Gfree Bio
112. Gilead Sciences
113. Greenpharma
114. GSK
115. GTCR
116. GVK Biosciences
117. HarkerBIO
118. HD Biosciences
119. Health Economics Research Centre
120. Icagen
121. IDSC
122. ImaBiotech
123. In Vitro ADMET Laboratories
124. Innovative Informatica Technologies
125. Inpharmatica
126. InrexTest
127. INSERM
128. International Resources Group
129. INVITEK
130. IONTOX
131. IOTA Pharmaceuticals
132. Japan Pharmaceutical Manufacturers Association
133. Janssen Therapeutics
134. JOINN Laboratories
135. JPT Peptide Technologies
136. JRF GLOBAL
137. Jubilant Biosys
138. Kirklees Biosciences
139. KWS BioTest
140. LabCorp
141. Labo Van Poucke
142. Laxai Avanti Life Sciences
143. LegoChem Biosciences
144. Longthera Pharmaceuticals
145. Mascot Industries
146. MasiMax Resources
147. Mayo Clinic
148. Medisyn Technologies
149. Merck
150. MetaSafe
151. Metrion Biosciences
152. MicroConstants
153. Mind the Byte
154. Molcode
155. Molsoft
156. MorphoSys
157. MPI Research
158. MTTlab
159. Nanolab Technologies
160. National Institute of Allergy and Infectious Disease
161. National Institutes of Health
162. Neuro-Sys
163. NMDL-LCPL
164. Notox
165. NovaData Solutions
166. Novamass
167. NovaMechanics
168. Novartis
169. Novo Informatics
170. NuChem Therapeutics
171. Nuevolution
172. NuGEN Technologies
173. Numerate
174. Oncodesign
175. Optivia Biotechnology
176. Oroxcell
177. Oxford Bioscience Partners
178. Panlabs Biologics
179. PathoQuest
180. PerkinElmer
181. Petra Pharma
182. Pfizer
183. PharmaCadence
184. Pharmacelsus
185. Pharmaceuticals and Medical Devices Agency
186. Pharmaceutical Product Development
187. Pharmaron
188. Pharmidex Pharmaceutical Services
189. PharmOptima
190. PHAST
191. Piramal Pharma Solutions
192. Porton Pharma Solutions
193. Preclinical GPS
194. Prestwick Chemical
195. Prime European Therapeuticals
196. Princeton BioMolecular Research
197. Profacgen
198. ProSciens
199. Prosilico
200. ProtoQSAR
201. ProXyChem
202. Q2 Solutions
203. Q3 Analytical
204. Qualyst Transporter Solutions
205. Quantum Hi-Tech
206. Quintara Discovery
207. Quotient Bioresearch
208. ReadyCell
209. Rebexsess Discovery Chemistry
210. Red Glead Discovery
211. Regulus Therapeutics
212. ResearchPoint Global
213. Rosa
214. RTI International
215. Sai Life Sciences
216. Sandexis
217. Sanofi
218. Schrödinger
219. Sekisui Medical
220. Sekisui XenoTech
221. Selcia
222. Selvita
223. Shanghai ChemPartner
224. Shanghai Medicilon
225. Shechter Computational Solutions
226. Shire
227. Sigma-Aldrich
228. SilcsBio
229. Simulations Plus
230. SNBL USA
231. SOLVO Biotechnology
232. Spectris
233. SPEware
234. SRI International
235. Strand Life Sciences
236. Suven Life Sciences
237. Sygnature Discovery
238. Syngene
239. Synovo
240. Syntegrity Group
241. TCG Lifesciences
242. Tecan
243. TestAmerica
244. TetraQ
245. The Carlyle Group
246. The Institute for Transfusion Medicine
247. The Michael J Fox Foundation
248. Touchstone Biosciences
249. TPG Capital
250. Triskelion
251. Unilabs
252. University of California
253. University of Pittsburgh
254. Vanta Bioscience
255. Villapharma Research
256. Vipragen Biosciences
257. Vitalant Research Institute
258. Viva Biotech
259. Vivo Bio Tech
260. Vivotecnia
261. WIL Research Laboratories
262. Wildcard Pharmaceutical Consulting
263. WuXi AppTec
264. Xceleron
265. XenoBiotic Laboratories
266. Xenometrics
267. XenoTech
268. XtalPi
269. Zumutor Biologic